Mallika Mundkur | Former Deputy Chief Medical Officer, United States Food and Drug Administration
FDA

Mallika L. Mundkur, MD, MPH, is a physician scientist who spent nearly a decade at the U.S. Food and Drug Administration, most recently as Deputy Chief Medical Officer in the Office of the Commissioner. In that role, she led several FDA-wide modernization efforts, including review modernization efforts, the Agency's first cross-center council on real-world evidence, and development of a modernized Sentinel 2.0 framework. She also partnered with FDA's Chief AI Officer and the Commissioner on a proposed framework for the Real-Time Clinical Trials initiative. Earlier in her FDA career, her scientific work on opioid prescribing was published in major medical journals, cited in Congressional testimony, and informed the 2022 federal opioid prescribing guideline. She now advises and invests in early- and late-stage biotech and medical device startups internationally. Dr. Mundkur holds a BA in biochemistry from Harvard College, an MD from the University of Massachusetts Medical School, and an MPH from the Harvard T.H. Chan School of Public Health. She completed her internal medicine residency at the University of Alabama at Birmingham, where she served as Chief Medical Resident, with subsequent training in clinical informatics at the National Library of Medicine and in pharmacoepidemiology at Brigham and Women's Hospital and Harvard Medical School. She maintains an active clinical practice as a volunteer internist and is a Clinical Assistant Professor at the George Washington University School of Medicine.